Hello PB, I am not saying that. What I am saying is that my source felt that an anti-CD4 antibody might have risks associated with it's reaction with various immune system cells.
He felt that this was a common problem in the past and that it could very easily turn out to be the case again. I trust him because he has much experience in the field.
I am alarmed at the moment because, as we all know, suddenly CE9.1 may have such a problem although, it so far looks only like they suspect that it has. My concern is that it will turn out that it, in fact does.
This stems from the following...
- SBH and, to some extent, IDEC insiders, begin selling large numbers of shares.
- I have a discussion with my source who is also concerned about this and tells me his opinion about anti-CD4 antibodies which I take seriously becuase of the sell-off which was occuring at that time.
- Eric Hecht, who has always had IDPH at "Strong Buy", starts IDEC at "accumulate".
- SBH and IDPH announce that Phase III has been temporarily suspended for CE9.1.
Although all these events could be individually explained away, I think taken together they are alarming and suggest that perhaps SBH thinks that CE9.1 is not a viable drug candidate. That is an opinion, of course.
The plan II backup...? If SBH was backing this one, I would be concerned. As far as I can tell, they sold every share of IDEC stock they ever had. Again, I am forming an opinion on why they did this but, taking all these factors together, it doesn't look good for CE9.1 and any back-up wasn't good enough to keep SBH around if indeed that back-up were sponsored by them.
Although I was not long, I do have some IDPH calls and it doesn't look good for those. I suppose I just felt that even though I thought that in light of SBH's massive selling and the opinion I'd heard about therapies like CE9.1 that something might be up, I didn't totally trust my instincts on this one!
BENNETT |
